Page last updated: 2024-08-26

bosentan anhydrous and Cardiac Failure

bosentan anhydrous has been researched along with Cardiac Failure in 85 studies

Research

Studies (85)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's17 (20.00)18.2507
2000's51 (60.00)29.6817
2010's14 (16.47)24.3611
2020's3 (3.53)2.80

Authors

AuthorsStudies
Fu, S; Li, Z; Ma, X; Sun, Z; Wang, A; Wang, Y; Zhang, D1
Geiger, R; Kiechl-Kohlendorfer, U; Michel, M; Podnar, T; Ralser, E; Schermer, E; Stock, K1
Chi, J; Dong, B; Huang, Y; Lv, W; Wang, YG; Zhou, Y1
Caspi, A; DeMets, D; Kiowski, W; Kobrin, I; Krum, H; Massie, BM; McMurray, JJV; Packer, M; Petrie, MC; Pratt, CM; Roux, S; Swedberg, K1
Fujimi, K; Fukuda, Y; Hiratsuka, M; Iwasaki, A; Miura, S; Nishikawa, H; Saku, K; Shiraishi, T; Yanagisawa, J; Yano, M1
Ewald, GA; Garcia-Cortes, R; LaRue, SJ; Nassif, ME; Rasalingham, R; Ravichandran, A; Ray, S; Schilling, JD; Silvestry, SC; Vader, JM; Wang, IW1
Aversa, M; Granton, J; Porter, S1
Goldberg, DJ; Paridon, SM; Rychik, J; Snarr, BS1
Akagi, S; Dan, K; Fujimoto, Y; Hisamatsu, K; Ikeda, E; Matsubara, H; Miyaji, K; Munemasa, M; Ohe, T; Tokunaga, N1
Hoepf, TM; Holycross, BJ; McCune, SA; Radin, MJ1
Broomé, M; Frenckner, B; Lindström, M; Radell, P1
Emoto, N; Hirata, K; Iwasa, N; Kato, H; Kawai, H; Kuroda, Y; Matsuo, N; Miyagawa, K; Ohnishi, T; Yoshida, A1
Dhalla, NS; Rehsia, NS1
Castel, A; Farrero, M; Perez-Villa, F; Roig, E; Sionis, A1
Dupuis, J; Jiang, BH; Shi, Y; Tardif, JC1
de Man, FS; Handoko, ML; Vonk-Noordegraaf, A1
Akita, C; Hashimoto, Y; Hirono, K; Horiuchi, I; Ichida, F; Kato, Y; Miyawaki, T; Nakamura, T; Nakayama, T; Saji, T; Taguchi, M; Yoshimura, N1
Fuchs, U; Gummert, JF; Hefke, T; Schulte-Eistrup, S; Schulz, U; Zittermann, A1
Iwamoto, Y; Kawasaki, H; Senzaki, H; Taketazu, M; Tamai, A1
Aizawa, T; Hatano, M; Inaba, T; Kinugawa, K; Maki, H; Nagai, R; Shiga, T; Yamashita, T; Yao, A1
Hatano, M; Imamura, T; Inaba, T; Kato, N; Kinugawa, K; Kyo, S; Maki, H; Minatsuki, S; Muraoka, H; Nagai, R; Ono, M; Shiga, T; Yao, A1
Teerlink, JR2
Cherubini, A; Di Lenarda, A; Perkan, A; Salvatore, L; Sinagra, G1
Coats, AJ; Kalra, PR; Moon, JC1
Hussar, DA1
Begin, KJ; Gorga, JA; Kihara, Y; LeWinter, MM; Noguchi, T; Palmiter, KA; VanBuren, P1
Gosek, K; Grzeszczak, W; Zukowska-Szczechowska, E1
Lüscher, TF; Spieker, LE2
Piuhola, J; Ruskoaho, H; Szokodi, I1
Inagaki, K; Iwanaga, Y; Izumi, T; Kihara, Y; Kita, T; Noma, A; Onozawa, Y; Sarai, N; Takenaka, H; Yoneda, T1
Chin, KM; Kim, NH; Rubin, LJ1
Anderson, S; Caspi, A; Charlon, V; Cohen-Solal, A; Demets, DL; Kiowski, W; Kostuk, W; Krum, H; Levine, B; Massie, BM; McMurray, J; Packer, M; Rizzon, P; Soler, J; Swedberg, K1
Gottlieb, SS1
Matsumori, A1
Hirata, Y; Kanno, K1
Halank, M; Hoeffken, G; Kolditz, M; Miehlke, S; Schiemanck, S; Schmeisser, A1
Musch, A1
Hirata, Y; Yoshimoto, T1
Alfano, D; Argiento, P; Calabrò, R; Cotrufo, M; D'Alto, M; Galdieri, N; Maiello, C; Russo, MG; Santoro, G; Sarubbi, B1
Batyraliev, TA; Ekinsi, E; Makhmutkhodzhaev, SA; Pataraia, SA; Pershukov, IV; Preobrazhenskiĭ, DV; Sidorenko, BA1
Park, MH1
Bertel, O; Hunziker, P; Jones, R; Kim, J; Kiowski, W; Müller, P; Oechslin, E; Schmitt, R; Sütsch, G1
Clozel, JP; Clozel, M; Hess, P; Löffler, BM; Maire, JP; Teerlink, JR1
Webb, DJ1
Kaddoura, S; Poole-Wilson, PA1
Borzak, S; Goldstein, S; Sabbah, HN; Scicli, G; Shevlyagin, S; Shimoyama, H; Tanimura, M1
Abassi, Z; Better, OS; Gurbanov, K; Hoffman, A; Rubinstein, I; Winaver, J1
Yamazaki, T; Yazaki, Y1
Bertel, O; Kiowski, W; Sütsch, G1
Burnier, M1
Comoy, E; Compagnon, P; Derumeaux, G; Henry, JP; Hogie, M; Lallemand, F; Letac, B; Macé, B; Mulder, P; Richard, V; Thuillez, C1
Attramadal, H; Bjønerheim, R; Grogaard, HK; Kongshaug, H; Oie, E; Smiseth, OA1
Bertel, O; Christen, S; Hunziker, P; Kim, JH; Kiowski, W; Rickenbacher, P; Strobel, W; Sütsch, G; Yan, XW1
Colucci, WS; Sam, F1
Barbe, F; Carayon, A; Choussat, R; Crozatier, B; Hittinger, L; Maistre, G; Su, J1
Breu, V; Clozel, M; Ertel, SI; Roux, S1
Goldstein, S; Mishima, T; Sabbah, HN; Sharov, VG; Suzuki, G; Tanimura, M; Todor, A1
Bertel, O; Clozel, M; Kiowski, W; Nicholls, MG; Rickenbacher, P; Sütsch, G; Yandle, TG1
Clozel, M; Roux, S1
Bauersachs, J; Ertl, G; Fraccarollo, D; Galuppo, P; Widder, J1
Cleland, JG; Mylona, P1
Clozel, M1
Kiowski, W; Sütsch, G1
Clair, MJ; de Gasparo, M; Hendrick, JW; King, MK; Mandel, J; McElmurray, JH; Mukherjee, R; New, RB; Sampson, AC; Spinale, FG1
Chen, YF; Oparil, S1
Abassi, Z; Calis, KA; Charlon, V; Choucair, WK; Ellahham, SH1
Abraham, WT; Lamba, S; Suresh, DP1
McMurray, J; Seed, A1
Lüscher, TF; Noll, G; Ruschitzka, FT; Spieker, LE1
Ferdinand, KC1
Bertel, O; Kiowski, W; Oechslin, E; Sütsch, G1
Clozel, M; Feuerstein, G; Nambi, P1
Inagaki, K; Iwanaga, Y; Kataoka, K; Kihara, Y; Onozawa, Y; Sasayama, S; Yoneda, T1
Poole-Wilson, PA; van Veldhuisen, DJ1
Cheng, TO1
Chin, BS; Lip, GY1
Enseleit, F; Hürlimann, D; Lüscher, TF; Noll, G; Ruschitzka, F1
Bertel, O; Brunner-Larocca, HP; Kiowski, W; Oechslin, E; Schalcher, C; Suetsch, G1
Clozel, JP; Clozel, M; Ding, SS; Hess, P; Qiu, C; Xi, JF1
Attramadal, H; Clausen, OP; Grøgaard, HK; Oie, E; Yndestad, A; ØIje, E1
Roux, S; Rubin, LJ1

Reviews

33 review(s) available for bosentan anhydrous and Cardiac Failure

ArticleYear
Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials.
    Diabetic medicine : a journal of the British Diabetic Association, 2021, Volume: 38, Issue:1

    Topics: Albuminuria; Atrasentan; Bosentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin Receptor Antagonists; Heart Failure; Humans; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic

2021
Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials.
    JACC. Heart failure, 2017, Volume: 5, Issue:5

    Topics: Aged; Australia; Bosentan; Cause of Death; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Endothelin Receptor Antagonists; Europe; Female; Heart Failure; Humans; Internationality; Kaplan-Meier Estimate; Male; Middle Aged; Morbidity; North America; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Sulfonamides; Survival Analysis; Time Factors; Treatment Outcome

2017
Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.
    Drug safety, 2015, Volume: 38, Issue:5

    Topics: Animals; Antihypertensive Agents; Bosentan; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug Monitoring; Endothelin Receptor Antagonists; Heart Failure; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Pyrimidines; Risk; Sulfonamides

2015
Pulmonary vasodilator therapy in the failing Fontan circulation: rationale and efficacy.
    Cardiology in the young, 2015, Volume: 25, Issue:8

    Topics: Bosentan; Cardiac Output; Endothelin Receptor Antagonists; Fontan Procedure; Heart Defects, Congenital; Heart Failure; Humans; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Postoperative Complications; Pulmonary Circulation; Pyridazines; Sildenafil Citrate; Sulfonamides; Vascular Resistance; Vasodilator Agents

2015
Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.
    Heart failure reviews, 2010, Volume: 15, Issue:1

    Topics: Angiotensin II; Animals; Antidiuretic Agents; Antihypertensive Agents; Benzazepines; Biomarkers; Bosentan; Catecholamines; Drug Therapy, Combination; Endothelin-1; Heart Failure; Humans; Peptides, Cyclic; Renin-Angiotensin System; Sulfonamides; Sympathetic Nervous System; Tolvaptan; Treatment Outcome; Vasopressins

2010
[Treatment of heart failure: an update].
    Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 2002, Volume: 3, Issue:7

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Antihypertensive Agents; Benzazepines; Bosentan; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Defibrillators, Implantable; Double-Blind Method; Heart Failure; Heart-Assist Devices; Humans; Metoprolol; Multicenter Studies as Topic; Placebos; Propanolamines; Prospective Studies; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Sulfonamides; Tetrazoles; Valine; Valsartan; Vasodilator Agents

2002
[Antihypertensive treatment in patients with diabetes mellitus].
    Polskie Archiwum Medycyny Wewnetrznej, 2002, Volume: 108, Issue:4

    Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Bosentan; Diabetes Complications; Endothelins; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic; Losartan; Sulfonamides; Time Factors

2002
Will endothelin receptor antagonists have a role in heart failure?
    The Medical clinics of North America, 2003, Volume: 87, Issue:2

    Topics: Animals; Bosentan; Cardiovascular Agents; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Humans; Isoxazoles; Oligopeptides; Peptides, Cyclic; Phenylpropionates; Piperidines; Pyridines; Pyrimidines; Sulfonamides; Tetrazoles; Thiophenes; Treatment Outcome

2003
The right ventricle in pulmonary hypertension.
    Coronary artery disease, 2005, Volume: 16, Issue:1

    Topics: Bosentan; Cardiac Output; Chronic Disease; Drug Therapy, Combination; Epoprostenol; Female; Heart Failure; Heart Function Tests; Heart Ventricles; Humans; Hypertension, Pulmonary; Male; Prognosis; Risk Assessment; Severity of Illness Index; Stroke Volume; Sulfonamides; Survival Rate; Treatment Outcome; Ventricular Dysfunction, Right; Ventricular Function

2005
[Cytokine antagonists and endothelin antagonists for therapy of heart failure].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2005, Feb-10, Volume: 94, Issue:2

    Topics: Angiotensin II; Animals; Antibodies, Monoclonal; Bosentan; Clinical Trials as Topic; Cytokines; Endothelins; Etanercept; Genetic Therapy; Heart Failure; Humans; Immunoglobulin G; Infliximab; Interleukin-10; Mast Cells; NF-kappa B; Proto-Oncogene Proteins c-kit; Pyridazines; Receptors, Tumor Necrosis Factor; Sulfonamides

2005
[Endothelin].
    Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 8

    Topics: Animals; Arteriosclerosis; Biomarkers; Bosentan; Diagnostic Techniques, Endocrine; Drug Design; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Humans; Hypertension; Hypertension, Pulmonary; Receptors, Endothelin; Reference Values; Sulfonamides

2005
Endothelins: pathophysiology and treatment implications in chronic heart failure.
    Current heart failure reports, 2005, Volume: 2, Issue:4

    Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Humans; Peptides, Cyclic; Receptors, Endothelin; Sulfonamides; Treatment Outcome; Vasoconstriction

2005
[Pulmonary arterial hypertension. Therapy with the endothelin-1 receptor antagonist bosentan].
    Medizinische Monatsschrift fur Pharmazeuten, 2006, Volume: 29, Issue:7

    Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Heart Failure; Humans; Hypertension, Pulmonary; Randomized Controlled Trials as Topic; Scleroderma, Systemic; Sulfonamides

2006
[Bosentan for treatment of heart failure].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, May-28, Volume: 65 Suppl 5

    Topics: Animals; Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Humans; Hypertension, Pulmonary; Sulfonamides; Ventricular Remodeling

2007
[Pulmonary hypertension and right ventricular failure. Part XI. Endothelin receptor blockers in the treatment of primary pulmonary arterial hypertension].
    Kardiologiia, 2007, Volume: 47, Issue:7

    Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Sulfonamides; Thiophenes; Ventricular Dysfunction, Right

2007
Advances in diagnosis and treatment in patients with pulmonary arterial hypertension.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2008, Feb-01, Volume: 71, Issue:2

    Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Disease Progression; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelium, Vascular; Epoprostenol; Heart Failure; Humans; Hypertension, Pulmonary; Iloprost; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Platelet Aggregation Inhibitors; Prognosis; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Vasoconstriction

2008
[Endothelial factors and cardiac insufficiency].
    Praxis, 1997, Feb-11, Volume: 86, Issue:7

    Topics: Bosentan; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Humans; Nitric Oxide; Sulfonamides

1997
Endothelin-1 in heart failure: does it play a role?
    Cardiologia (Rome, Italy), 1998, Volume: 43, Issue:9

    Topics: Animals; Bosentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Heart Failure; Hemodynamics; Humans; Mice; Myocardial Infarction; Myocardium; Peptides, Cyclic; Rats; Receptors, Endothelin; Stroke Volume; Sulfonamides; Time Factors

1998
Endothelin antagonism with bosentan: a review of potential applications.
    Journal of molecular medicine (Berlin, Germany), 1999, Volume: 77, Issue:4

    Topics: Animals; Antihypertensive Agents; Bosentan; Endothelins; Heart Failure; Humans; Hypertension; Kinetics; Rats; Subarachnoid Hemorrhage; Sulfonamides; Time Factors

1999
[The pharmacology of endothelin and its antagonist bosentan].
    Annales d'endocrinologie, 2000, Volume: 61, Issue:1

    Topics: Animals; Bosentan; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Humans; Hypertension; Hypertension, Pulmonary; Sulfonamides

2000
Endothelin receptor antagonists: current status and perspectives.
    Journal of cardiovascular pharmacology, 2000, Volume: 35, Issue:4 Suppl 2

    Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Heart Failure; Humans; Hypertension; Subarachnoid Hemorrhage; Sulfonamides; Vasospasm, Intracranial

2000
Endothelin and endothelin receptor antagonism in heart failure.
    Journal of cardiovascular pharmacology, 2000, Volume: 35, Issue:4 Suppl 2

    Topics: Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Hemodynamics; Humans; Sulfonamides; Vasoconstriction

2000
Endothelial dysfunction in the pulmonary vascular bed.
    The American journal of the medical sciences, 2000, Volume: 320, Issue:4

    Topics: Animals; Antihypertensive Agents; Atrasentan; Bosentan; Controlled Clinical Trials as Topic; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Endothelium, Vascular; Epoprostenol; Heart Failure; Humans; Hypertension, Pulmonary; Hypoxia; Lung Diseases, Obstructive; Nitric Oxide; Oligopeptides; Peptides, Cyclic; Piperidines; Pulmonary Circulation; Pyrrolidines; Receptors, Endothelin; RNA, Messenger; Sulfonamides; Time Factors; Vasoconstriction; Vasodilation

2000
Bosentan and the endothelin system in congestive heart failure.
    Clinical cardiology, 2000, Volume: 23, Issue:11

    Topics: Animals; Antihypertensive Agents; Bosentan; Controlled Clinical Trials as Topic; Dogs; Double-Blind Method; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Heart Failure; Hemodynamics; Humans; Placebos; Rats; Receptors, Endothelin; Sulfonamides; Time Factors

2000
New developments in heart failure: role of endothelin and the use of endothelin receptor antagonists.
    Journal of cardiac failure, 2000, Volume: 6, Issue:4

    Topics: Bosentan; Carboxylic Acids; Chronic Disease; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Humans; Indans; Peptides, Cyclic; Prognosis; Pyridines; Pyrimidines; Receptors, Endothelin; Sulfonamides; Treatment Outcome

2000
Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?
    Journal of the American College of Cardiology, 2001, Volume: 37, Issue:6

    Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Forecasting; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Myocardial Contraction; Peptides, Cyclic; Phenylpropionates; Predictive Value of Tests; Prognosis; Pyrimidines; Sulfonamides; Time Factors; Vascular Resistance; Vasoconstriction; Ventricular Function, Left

2001
Update in pharmacologic treatment of hypertension.
    Cardiology clinics, 2001, Volume: 19, Issue:2

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteriosclerosis; Bosentan; Bradykinin; Calcium Channel Blockers; Diabetes Complications; Diuretics; Drug Therapy, Combination; Endothelin-1; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Patient Compliance; Pyridines; Quality of Life; Renal Insufficiency; Renin-Angiotensin System; Risk Factors; Sulfonamides; Systole; Thiazepines; Treatment Outcome

2001
Hemodynamic effects of bosentan in patients with chronic heart failure.
    Heart failure reviews, 2001, Volume: 6, Issue:4

    Topics: Bosentan; Chronic Disease; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Hemodynamics; Humans; Receptors, Endothelin; Sulfonamides

2001
Endothelin and heart failure.
    Heart failure reviews, 2001, Volume: 6, Issue:4

    Topics: Bosentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Hemodynamics; Humans; Receptors, Endothelin; Sulfonamides

2001
The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure.
    International journal of cardiology, 2001, Volume: 80, Issue:1

    Topics: Bosentan; Cardiovascular Agents; Deoxyepinephrine; Heart Failure; Humans; Imidazoles; Mibefradil; Pyrazines; Quinolines; Sulfonamides; Xamoterol

2001
New pharmacological strategies for the treatment of heart failure.
    Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:7

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atrial Natriuretic Factor; Bosentan; Calcium; Cardiotonic Agents; Clinical Trials as Topic; Endothelin-1; Heart Failure; Humans; Hydrazones; Muscle Proteins; Neprilysin; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Sulfonamides; Tumor Necrosis Factor-alpha

2001
Endothelin antagonists and heart failure.
    Current hypertension reports, 2002, Volume: 4, Issue:1

    Topics: Atrasentan; Bosentan; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Hemodynamics; Humans; Hypertension; Pyrrolidines; Receptors, Endothelin; Sulfonamides

2002
Bosentan: a dual endothelin receptor antagonist.
    Expert opinion on investigational drugs, 2002, Volume: 11, Issue:7

    Topics: Animals; Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Humans; Hypertension, Pulmonary; Models, Animal; Sulfonamides

2002

Trials

10 trial(s) available for bosentan anhydrous and Cardiac Failure

ArticleYear
Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol.
    Circulation journal : official journal of the Japanese Circulation Society, 2008, Volume: 72, Issue:7

    Topics: Adult; Antihypertensive Agents; Bosentan; Child; Drug Synergism; Drug Therapy, Combination; Epoprostenol; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Treatment Outcome

2008
Therapy with sildenafil or bosentan decreases pulmonary vascular resistance in patients ineligible for heart transplantation because of severe pulmonary hypertension.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2010, Volume: 29, Issue:7

    Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Bosentan; Contraindications; Heart Failure; Heart Transplantation; Humans; Hypertension, Pulmonary; Piperazines; Prospective Studies; Purines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; Vascular Resistance; Vasodilator Agents

2010
Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?
    International journal of cardiology, 2002, Volume: 85, Issue:2-3

    Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Heart Failure; Hospitalization; Humans; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome

2002
Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study.
    Journal of cardiac failure, 2005, Volume: 11, Issue:1

    Topics: Aged; Antihypertensive Agents; Bosentan; Double-Blind Method; Erythrocyte Count; Female; Heart Failure; Hemoglobins; Hospitalization; Humans; Male; Middle Aged; Sulfonamides; Survival Analysis; Treatment Failure

2005
Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure.
    Lancet (London, England), 1995, Sep-16, Volume: 346, Issue:8977

    Topics: Adult; Aged; Bosentan; Double-Blind Method; Endothelin Receptor Antagonists; Endothelins; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Sulfonamides; Vasoconstriction

1995
Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Endothelin antagonism in heart failure.
    Circulation, 1995, Dec-15, Volume: 92, Issue:12

    Topics: Bosentan; Double-Blind Method; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Humans; Sulfonamides; Vasoconstriction

1995
Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans.
    Cardiovascular drugs and therapy, 1997, Volume: 10, Issue:6

    Topics: Administration, Oral; Adult; Aged; Blood Pressure; Bosentan; Chronic Disease; Double-Blind Method; Endothelin Receptor Antagonists; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Receptor, Endothelin A; Sulfonamides; Time Factors; Vascular Resistance

1997
Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure.
    Circulation, 1998, Nov-24, Volume: 98, Issue:21

    Topics: Administration, Oral; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Bosentan; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Endothelin Receptor Antagonists; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prospective Studies; Receptor, Endothelin A; Sulfonamides; Treatment Outcome

1998
Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins.
    The American journal of cardiology, 2000, Apr-15, Volume: 85, Issue:8

    Topics: Aldosterone; Angiotensin II; Antihypertensive Agents; Bosentan; Double-Blind Method; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Humans; Middle Aged; Sulfonamides

2000
Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team.
    European journal of heart failure, 1999, Volume: 1, Issue:2

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Double-Blind Method; Endothelins; Europe; Female; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Sulfonamides; Survival Rate; United States; Ventricular Function, Left

1999

Other Studies

42 other study(ies) available for bosentan anhydrous and Cardiac Failure

ArticleYear
Heart failure with preserved ejection fraction and non-alcoholic fatty liver disease: new insights from bioinformatics.
    ESC heart failure, 2023, Volume: 10, Issue:1

    Topics: Bosentan; Computational Biology; Heart Failure; Humans; Non-alcoholic Fatty Liver Disease; Stroke Volume

2023
Presumed prenatal closure of foramen ovale and persistent pulmonary hypertension of the newborn.
    Cardiology in the young, 2020, Volume: 30, Issue:2

    Topics: Bosentan; Echocardiography; Female; Foramen Ovale; Heart Failure; Humans; Hypertension, Pulmonary; Infant, Newborn; Male; Pregnancy; Sildenafil Citrate; Treatment Outcome; Ultrasonography, Prenatal

2020
Effects of treatment with a combination of cardiac rehabilitation and bosentan in patients with pulmonary Langerhans cell histiocytosis associated with pulmonary hypertension.
    European journal of preventive cardiology, 2014, Volume: 21, Issue:12

    Topics: Adult; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Exercise Therapy; Exercise Tolerance; Female; Heart Failure; Hemodynamics; Histiocytosis, Langerhans-Cell; Humans; Hypertension, Pulmonary; Positron-Emission Tomography; Recovery of Function; Sulfonamides; Time Factors; Tomography, X-Ray Computed; Treatment Outcome

2014
Treatment of secondary pulmonary hypertension with bosentan after left ventricular assist device implantation.
    Cardiovascular therapeutics, 2015, Volume: 33, Issue:2

    Topics: Antihypertensive Agents; Arterial Pressure; Bosentan; Endothelin Receptor Antagonists; Female; Heart Failure; Heart-Assist Devices; Humans; Hypertension, Pulmonary; Male; Middle Aged; Missouri; Prosthesis Design; Pulmonary Artery; Retrospective Studies; Sulfonamides; Time Factors; Treatment Outcome; Ventricular Function, Left

2015
Salt-induced cardiac hypertrophy is independent of blood pressure and endothelin in obese, heart failure-prone SHHF rats.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2008, Volume: 30, Issue:7

    Topics: Animals; Base Sequence; Blood Pressure; Bosentan; Cardiomegaly; DNA Primers; Endothelin Receptor Antagonists; Endothelins; Gene Expression; Heart Failure; Leptin; Male; Nitric Oxide Synthase; Obesity; Rats; RNA, Messenger; Sodium Chloride, Dietary; Sulfonamides

2008
Platelet-derived growth factor inhibition--a new treatment of pulmonary hypertension in congenital diaphragmatic hernia?
    Journal of pediatric surgery, 2008, Volume: 43, Issue:10

    Topics: Benzamides; Bosentan; Combined Modality Therapy; Continuous Positive Airway Pressure; Diuretics; Enteral Nutrition; Extracorporeal Membrane Oxygenation; Heart Failure; Hernia, Diaphragmatic; Hernias, Diaphragmatic, Congenital; Humans; Hypertension, Pulmonary; Hypoxia; Iloprost; Imatinib Mesylate; Infant, Newborn; Male; Nitric Oxide; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Sildenafil Citrate; Sulfonamides; Sulfones

2008
[Remarkable response of bosentan, an endothelin receptor antagonist, for a patient with Eisenmenger syndrome].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2008, Oct-10, Volume: 97, Issue:10

    Topics: Aged; Bosentan; Eisenmenger Complex; Endothelin Receptor Antagonists; Female; Heart Failure; Heart Septal Defects, Atrial; Humans; Hypertension, Pulmonary; Sulfonamides; Treatment Outcome

2008
Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure.
    The European respiratory journal, 2011, Volume: 37, Issue:3

    Topics: Animals; Antihypertensive Agents; Bosentan; Disease Models, Animal; Echocardiography; Endothelin Receptor Antagonists; Heart Failure; Heart Ventricles; Hemodynamics; Hypertension, Pulmonary; Lung; Myocardial Infarction; Prognosis; Rats; Sulfonamides

2011
The rise and fall of endothelin receptor antagonists in congestive heart failure.
    The European respiratory journal, 2011, Volume: 37, Issue:3

    Topics: Animals; Antihypertensive Agents; Bosentan; Cardiology; Disease Models, Animal; Endothelin Receptor Antagonists; Heart; Heart Failure; Humans; Hypertension, Pulmonary; Myocardium; Prognosis; Sulfonamides

2011
Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension.
    Drug metabolism and pharmacokinetics, 2011, Volume: 26, Issue:3

    Topics: Adolescent; Age Factors; Aryl Hydrocarbon Hydroxylases; Asian People; Bayes Theorem; Body Weight; Bosentan; Child; Child, Preschool; Computer Simulation; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Drug Interactions; Familial Primary Pulmonary Hypertension; Female; Genotype; Heart Failure; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; Liver-Specific Organic Anion Transporter 1; Male; Models, Biological; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Piperazines; Polymorphism, Single Nucleotide; Purines; Sildenafil Citrate; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfonamides; Sulfones

2011
Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation.
    The Thoracic and cardiovascular surgeon, 2012, Volume: 60, Issue:1

    Topics: Adult; Aged; Analysis of Variance; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Germany; Heart Failure; Heart Transplantation; Hemodynamics; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Odds Ratio; Propensity Score; Proportional Hazards Models; Pulmonary Artery; Retrospective Studies; Sulfonamides; Time Factors; Treatment Outcome; Waiting Lists

2012
Late clinical manifestations of mitral valve disease and severe pulmonary hypertension in a patient diagnosed with premature closure of foramen ovale during fetal life.
    World journal of pediatrics : WJP, 2011, Volume: 7, Issue:2

    Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Fetal Diseases; Foramen Ovale; Heart Failure; Heart Valve Prosthesis Implantation; Humans; Hypertension, Pulmonary; Infant, Newborn; Male; Mitral Valve Stenosis; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Failure; Ultrasonography, Doppler, Pulsed; Ultrasonography, Prenatal; Vasodilator Agents

2011
Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension.
    International heart journal, 2011, Volume: 52, Issue:5

    Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Carbolines; Cardiac Output; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Echocardiography; Electrocardiography; Epoprostenol; Female; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Middle Aged; Sulfonamides; Tadalafil; Vasodilator Agents

2011
Bosentan improved persistent pulmonary hypertension in a case after implantation of a left ventricular assist device.
    Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs, 2013, Volume: 16, Issue:1

    Topics: Antihypertensive Agents; Bosentan; Heart Failure; Heart Transplantation; Heart-Assist Devices; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Treatment Outcome

2013
Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy?
    Journal of cardiac failure, 2002, Volume: 8, Issue:3

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Bosentan; Clinical Trials as Topic; Enalapril; Endothelin Receptor Antagonists; Female; Heart Failure; Humans; Male; Metalloendopeptidases; Middle Aged; Neurotransmitter Agents; Pyridines; Sulfonamides; Thiazepines; Treatment Outcome

2002
New drugs 2002, part III.
    Nursing, 2002, Volume: 32, Issue:7

    Topics: Adenine; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Antihypertensive Agents; Antirheumatic Agents; Bone Resorption; Bosentan; Cephalosporins; Darbepoetin alfa; Diphosphonates; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Erythropoietin; Heart Failure; Humans; Hypoglycemic Agents; Imidazoles; Indoles; Insulin; Insulin Aspart; Interleukin 1 Receptor Antagonist Protein; Natriuretic Agents; Natriuretic Peptide, Brain; Organophosphonates; Organophosphorus Compounds; Protein C; Recombinant Proteins; Serotonin Receptor Agonists; Sialoglycoproteins; Sulfonamides; Tenofovir; Tryptamines; Zoledronic Acid

2002
Altered myocardial thin-filament function in the failing Dahl salt-sensitive rat heart: amelioration by endothelin blockade.
    Circulation, 2003, Feb-04, Volume: 107, Issue:4

    Topics: Actin Cytoskeleton; Animals; Bosentan; Calcium; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Male; Muscle, Skeletal; Myocardial Contraction; Myocardium; Myofibrils; Phosphorylation; Protein Isoforms; Protein Kinase C; Rats; Rats, Inbred Dahl; Signal Transduction; Sulfonamides; Troponin T

2003
Endothelin receptor blockade and exacerbation of heart failure.
    Circulation, 2003, Jun-10, Volume: 107, Issue:22

    Topics: Animals; Bosentan; Chronic Disease; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelins; Heart; Heart Failure; Humans; Myocardial Contraction; Phenylpropionates; Pyrimidines; Rats; Receptor, Endothelin A; Sulfonamides; Vascular Resistance; Water-Electrolyte Balance

2003
Endothelin receptor antagonists in heart failure--a refutation of a bold conjecture?
    European journal of heart failure, 2003, Volume: 5, Issue:4

    Topics: Antihypertensive Agents; Bosentan; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Heart Failure; Humans; Sulfonamides; Treatment Outcome

2003
Reinduction of T-type calcium channels by endothelin-1 in failing hearts in vivo and in adult rat ventricular myocytes in vitro.
    Circulation, 2003, Nov-18, Volume: 108, Issue:20

    Topics: Angiotensin II; Animals; Antihypertensive Agents; Bosentan; Calcium Channels, T-Type; Cells, Cultured; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Heart Ventricles; Male; Myocytes, Cardiac; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; Sulfonamides

2003
The impact of finally publishing a negative study: new conclusions about endothelin antagonists.
    Journal of cardiac failure, 2005, Volume: 11, Issue:1

    Topics: Antihypertensive Agents; Bosentan; Heart Failure; Humans; Sulfonamides; Treatment Failure

2005
Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan.
    Wiener medizinische Wochenschrift (1946), 2005, Volume: 155, Issue:15-16

    Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Hypertension, Portal; Hypertension, Pulmonary; Iloprost; Injections, Intravenous; Liver Cirrhosis, Alcoholic; Male; Recurrence; Sulfonamides; Time Factors

2005
Complex multidrug therapy in a patient with pulmonary hypertension before and after orthotopic heart transplantation. A case report.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2007, Volume: 8, Issue:11

    Topics: Adult; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Cardiomyopathy, Restrictive; Contraindications; Drug Therapy, Combination; Epoprostenol; Heart Failure; Heart Transplantation; Humans; Hypertension, Pulmonary; Male; Sulfonamides

2007
Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan).
    Circulation, 1994, Volume: 90, Issue:5

    Topics: Animals; Blood Pressure; Bosentan; Chronic Disease; Cilazapril; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Male; Rats; Rats, Wistar; Sulfonamides

1994
Endothelin-1 in heart failure: a new therapeutic target?
    Lancet (London, England), 1996, Aug-17, Volume: 348, Issue:9025

    Topics: Animals; Bosentan; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Humans; Sulfonamides

1996
Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure.
    Circulation, 1996, Aug-15, Volume: 94, Issue:4

    Topics: Animals; Blood Pressure; Bosentan; Cardiac Output; Coronary Vessels; Diastole; Dogs; Echocardiography; Embolism; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Heart Rate; Hemodynamics; Norepinephrine; Sulfonamides; Time Factors; Vascular Resistance

1996
Bosentan improves renal regional blood flow in rats with experimental congestive heart failure.
    European journal of pharmacology, 1996, Aug-29, Volume: 310, Issue:2-3

    Topics: Animals; Bosentan; Disease Models, Animal; Heart Failure; Kidney; Male; Rats; Rats, Wistar; Regional Blood Flow; Sulfonamides

1996
Reversing congestive heart failure with endothelin receptor antagonists.
    Circulation, 1997, Apr-01, Volume: 95, Issue:7

    Topics: Aging; Angiotensin II; Animals; Bosentan; Cells, Cultured; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Humans; Mice; Mice, Transgenic; Rabbits; Receptors, Endothelin; Sulfonamides

1997
Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling.
    Circulation, 1997, Sep-16, Volume: 96, Issue:6

    Topics: Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Cardiac Volume; Chronic Disease; Collagen; Consciousness; Coronary Vessels; Cyclic GMP; Echocardiography; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Heart Failure; Heart Ventricles; Male; Myocardial Infarction; Myocardium; Norepinephrine; Pressure; Protein Precursors; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Survival Analysis; Ventricular Function, Left

1997
ET-receptor antagonism, myocardial gene expression, and ventricular remodeling during CHF in rats.
    The American journal of physiology, 1998, Volume: 275, Issue:3

    Topics: Angiotensinogen; Animals; Bosentan; Coronary Vessels; Endothelin Receptor Antagonists; Gene Expression; Heart Failure; Hypertrophy, Left Ventricular; Ligation; Male; Myocardial Infarction; Myocardium; Rats; Rats, Wistar; Receptor, Endothelin A; Receptors, Endothelin; RNA, Messenger; Sulfonamides; Ventricular Function, Left

1998
Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs.
    Cardiovascular research, 1998, Volume: 39, Issue:3

    Topics: Animals; Bosentan; Cardiac Output; Cardiac Pacing, Artificial; Dogs; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Female; Heart Failure; Hemodynamics; Male; Protein Precursors; Stroke Volume; Sulfonamides; Vasodilator Agents; Ventricular Dysfunction, Left; Ventricular Pressure

1998
Bosentan. RO 470203.
    Drugs in R&D, 1999, Volume: 2, Issue:1

    Topics: Animals; Antihypertensive Agents; Bosentan; Clinical Trials, Phase III as Topic; Drugs, Investigational; Heart Failure; Humans; Myocardial Ischemia; Randomized Controlled Trials as Topic; Rats; Sulfonamides

1999
Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure.
    Journal of the American College of Cardiology, 2000, Volume: 35, Issue:1

    Topics: Animals; Antihypertensive Agents; Bosentan; Disease Progression; Dogs; Heart Failure; Infusions, Intravenous; Myocardium; Stroke Volume; Sulfonamides; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling

2000
Endothelin-receptor blockade improves endothelial vasomotor dysfunction in heart failure.
    Cardiovascular research, 2000, Volume: 47, Issue:1

    Topics: Acetylcholine; Analysis of Variance; Animals; Aorta; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Heart Failure; In Vitro Techniques; Male; Myocardial Infarction; Nitroprusside; Oxygen; Phenylpropionates; Pyrimidines; Rats; Rats, Wistar; Renin; Sulfonamides; Superoxide Dismutase; Vasoconstrictor Agents; Vasodilator Agents

2000
Effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: effects on left ventricular performance.
    Circulation, 2000, Sep-19, Volume: 102, Issue:12

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bosentan; Cardiac Pacing, Artificial; Combined Modality Therapy; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Myocardial Contraction; Norepinephrine; Receptor, Endothelin A; Renin; Sulfonamides; Swine; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left

2000
Acute endothelin a receptor blockade in heart failure.
    Circulation, 2001, May-08, Volume: 103, Issue:18

    Topics: Antihypertensive Agents; Bosentan; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Heart Failure; Hemodynamics; Humans; Injections, Intravenous; Pulmonary Artery; Pulmonary Circulation; Receptor, Endothelin A; Sulfonamides; Vascular Resistance

2001
Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure.
    Circulation, 2001, Jul-31, Volume: 104, Issue:5

    Topics: Angiotensin II; Angiotensinogen; Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Disease Progression; Endothelin-1; Endothelins; Gene Expression Regulation; Heart Failure; Heart Ventricles; Hemodynamics; Hypertrophy, Left Ventricular; Male; Organ Size; Peptidyl-Dipeptidase A; Protein Precursors; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Survival Analysis; Thiazepines; Time Factors

2001
Endothelin receptor blockade in congestive heart failure.
    Circulation, 2001, Oct-30, Volume: 104, Issue:18

    Topics: Acute Disease; Antihypertensive Agents; Bosentan; Chronic Disease; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelin-1; Exercise Tolerance; Heart Failure; Hemodynamics; Humans; Phenylpropionates; Pyridines; Pyrimidines; Sulfonamides; Tetrazoles; Treatment Outcome; Vasodilator Agents

2001
Rationale and perspective of endothelin-1 antagonism in acute heart failure.
    Journal of cardiovascular pharmacology, 2001, Volume: 38 Suppl 2

    Topics: Acute Disease; Animals; Antihypertensive Agents; Bosentan; Dogs; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Humans; Peptides, Cyclic; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides

2001
Chronic endothelin receptor blockade prevents renal vasoconstriction and sodium retention in rats with chronic heart failure.
    Cardiovascular research, 2002, Volume: 53, Issue:4

    Topics: Animals; Antihypertensive Agents; Bosentan; Drug Administration Schedule; Endothelin Receptor Antagonists; Glomerular Filtration Rate; Heart Failure; Hemodynamics; Male; Myocardial Infarction; Natriuresis; Rats; Rats, Wistar; Renal Circulation; Sulfonamides; Vasoconstriction

2002
[2 studies for heart failure therapy. Endothelin receptor antagonist does not improve prognosis].
    MMW Fortschritte der Medizin, 2002, Apr-04, Volume: 144, Issue:14

    Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Heart Failure; Humans; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Failure

2002
Endothelin receptor antagonism attenuates cardiomyocyte apoptosis after induction of ischemia in rats.
    Scandinavian cardiovascular journal : SCJ, 2002, Volume: 36, Issue:2

    Topics: Animals; Apoptosis; Bosentan; Disease Models, Animal; Endothelin Receptor Antagonists; Gene Expression Regulation; Heart Failure; Male; Myocardial Ischemia; Myocardium; Rats; Rats, Wistar; Sulfonamides; Ventricular Remodeling

2002